Oncosil Medical Ltd has released a press release.
Appendix 4E and Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from OncoSil Medical
- Completion of Recruitment in TRIPP-FFX Clinical Trial
- Completion of Recruitment in PANCOSIL Study
- OSL announces $8.7m capital raise to drive commercialisation
- Consolidation/Split - OSL
- 120 German Hospitals entitled to negotiate fee for OncoSil
Later from OncoSil Medical
- Positive Preliminary Results from PANCOSIL Phase 1-2 Study
- Response to ASX Aware Letter
- OSPREY Analysis Shows Survival Benefit for OncoSil Patients
- OncoSil receives $1.84m R&D tax incentive
- Trading Halt
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical